Calcitonin gene‐related peptide levels in saliva of patients with burning mouth syndrome
- 23 December 2008
- journal article
- research article
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 38 (1) , 29-33
Abstract
Burning mouth syndrome (BMS) is an intraoral burning sensation for which no medical or dental cause can be found. Recent studies suggest that primary neuropathic dysfunction might be involved in the pathogenesis of BMS. Calcitonin gene-related peptide (CGRP) plays an important role in the development of pain and serves as a biological marker of trigeminovascular activation. The aim of this study was to determine the levels of CGRP in the saliva of BMS patients and estimate the trigeminovascular activation in BMS. CGRP levels were measured, by RIA method in 78 BMS patients and 16 healthy subjects. The levels of CGRP were non-significantly decreased in BMS patients in comparison to healthy subjects. These results suggest that trigeminal nerve degeneration may be the underlying cause of BMS.Keywords
This publication has 27 references indexed in Scilit:
- Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular systemThe Journal of Headache and Pain, 2008
- Novel migraine therapy with calcitonin gene-regulated peptide receptor antagonistsExpert Opinion on Therapeutic Targets, 2007
- Cerebral activation during thermal stimulation of patients who have burning mouth disorder: An fMRI studyPain, 2006
- Neurobiology in primary headachesBrain Research Reviews, 2005
- Trigeminal small-fiber sensory neuropathy causes burning mouth syndromePain, 2005
- Blockade of CGRP Receptors in the Intracranial Vasculature: A New Target in the Treatment of HeadacheCephalalgia, 2004
- A Report on the Journal 2004Cephalalgia, 2004
- The burning mouth syndrome remains an enigmaPain, 1995
- Lacunar Infarcts – A ReviewCerebrovascular Diseases, 1991
- Vasoactive peptide release in the extracerebral circulation of humans during migraine headacheAnnals of Neurology, 1990